Long-term effect of dutasteride as add-on therapy for benign prostatic hyperplasia with persistent overactive bladder symptoms after treatment of alpha-1 blocker

Long-term effect of dutasteride as add-on therapy for benign prostatic hyperplasia with persistent overactive bladder symptoms after treatment of alpha-1 blocker - Dutasteride as add-on therapy for overactive bladder symptoms

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000032082

Enrollment

Registered

2018-04-04

Start date

2015-06-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with benign prostatic hyperplasia who have overactive bladder symptom score of three points or higher after treatment of alpha-1 blocker for more than one year

Exclusion criteria

Exclusion criteria: Use of antimuscarinic drug, beta-3 adrenergic agonist or antiandrogen drug

Design outcomes

Primary

Measure	Time frame
Overactive bladder symptom score	—

Countries

Japan

Contacts

Public ContactYoshinori Tanaka

Hokkaido Prefectural Esashi Hospital Division of Urology

rinoshiyokanata@me.com0139-52-0036

Outcome results